ArticleFrontiers in cellular and infection microbiology2025
A single-center investigation on serotypes, drug resistance and clinical significance of GBS isolates from pregnant and non-pregnant adults in Baoji, China.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serotypes, sequence types, and erythromycin resistance of maternal colonizing group BFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the epidemiology, serotype distribution, and antimicrobial resistance of GBS among both pregnant and non-pregnant adults in Baoji, China, addressing an existing gap in current research. Methods: Based on the GBS strains identified in the clinical laboratory from 2016 to 2024, information on age, gender, specimen type, and diagnosis was collected for the corresponding adult cases, including both colonization and infection cases. GBS was identified using three methods: mass spectrometry, CAMP test and latex agglutination kit for streptococcal serotyping. Serotypes were determined by latex agglutination, and antimicrobial susceptibility was tested against 20 antimicrobials using an automated drug susceptibility system. Results: A total of 200 GBS strains were collected, in which 107 were from pregnant women, and 93 from non-pregnant adults including 34 males. Clinical pathogenic isolates were defined for 86 cases, in which the urinary tract infections were predominant (61.6%), and invasive infections were confirmed for 16 cases (18.6%). A total of 5 serotypes were identified in the present 200 strains, including serotype Ib (34.5%), V (26.0%), III (21.5%), Ia (2.0%) and VIII (1.0%). In addition, 30 strains (15.0%) were non-typeable (NT). The coverage rate of the hexavalent vaccine currently in development is 84.5%. Significant differences are observed in the proportions of serotypes Ib, III, and/or V across various age groups, pregnancy statuses, and between colonized and infectious strains. Notably, the proportion of serotype V varies markedly, with 32.3% in the 18-39 age group versus 18.9% in the 40-64 age group and 10% in the >64 age group, 36.4% in pregnant women compared to 14.0% in non-pregnant women, and 34.2% in colonized strains as opposed to 15.1% in infectious ones. All 200 GBS strains were sensitive to penicillin, and the resistance rates to erythromycin, azithromycin, levofloxacin, clindamycin, tetracycline, and chloramphenicol were 93.5%, 93.5%, 70.5%, 70.0%, 53.5%, and 13.0%, respectively. Conclusion: The present findings suggest that GBS may potentially infect and colonize adults, regardless of gender or age, in Baoji, China. Serotypes Ib, III, and V are common serotypes, but their frequency is related to the host's age group, pregnancy status, and clinical relevance. GBS isolates are still generally susceptible to penicillin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.